BlueReg continues to expand in the US opening its second North American office in Boston.
13 January 2020
Cambridge, Massachusetts, USA, December 13 2019, BlueReg, the consulting organization for life sciences companies, is announcing a development of its presence in North America by opening its second office in Boston in the United States.
Located at the heart of worldwide hub of life sciences at the CIC “Cambridge Innovation Center” (Kendall square), this new office aims to bring BlueReg closer to its existing and loyal customer base, to identify new opportunities, and to reinforce its commercial presence in the United States.
“2019 has been an important and transformative year for BlueReg. The opening of this new office in Boston is a key step in our ambition to continue to develop BlueReg internationally and especially in the United States,” explains Corinne Schmitz, CEO of BlueReg Group.
“The Boston area is an incredible breeding ground for pharmaceutical companies developing innovative treatments. We look forward to evolving in this highly dynamic environment and bringing our know-how to support these companies in making their health products available to patients with rare or serious diseases, especially in Europe.”
BlueReg is a consulting and service company specializing in life sciences and regulatory affairs. It offers strategic advice and hands-on / outsourcing solutions to life sciences companies, through the entire lifecycle of their products, from product development, registration through to launch, and product maintenance activities.
Initially created in 2011 in Sophia-Antipolis and Paris, France, BlueReg has subsequently developed to other locations in London (UK), New-York (US) and Amsterdam (Netherlands).
Leveraging on the experience and knowledge of its multidisciplinary experts and a solid reputation acquired within the French market, the company has become a privileged partner of French and international companies, in particular American ones, eager to conquer the European or French market. Today, the company supports more than a hundred pharmaceutical laboratories.
The BlueReg Group has also enriched its range of services and created Pharma Blue in France in 2015. As an operating pharmaceutical establishment, it allows both French and international biotech start-ups and companies to enable access to their innovative medicines under ATU (Temporary Authorizations of Use) facilitated by French agency ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé), and this before obtaining an MA (Marketing Authorization) in Europe.
Did you like this article? Share on social networks: